Choose a language and wait for the translated text.
The recombinant quadrivalent vaccine targets high-risk HPV strains which accounts for more than 70 per cent of cervical cancer cases globally. SII developed the vaccine in collaboration with DPT, BIRAC, WHO-IARC and the Gates Foundation.
